GW&K Investment Management LLC purchased a new stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 12,855 shares of the medical instruments supplier’s stock, valued at approximately $208,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Teachers Retirement System of The State of Kentucky boosted its position in AngioDynamics by 77.5% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 7,100 shares of the medical instruments supplier’s stock valued at $123,000 after buying an additional 3,100 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its position in AngioDynamics by 3.0% in the first quarter. Municipal Employees Retirement System of Michigan now owns 7,200 shares of the medical instruments supplier’s stock valued at $125,000 after buying an additional 210 shares during the last quarter. Mason Street Advisors LLC raised its stake in AngioDynamics by 8.5% in the first quarter. Mason Street Advisors LLC now owns 7,470 shares of the medical instruments supplier’s stock valued at $130,000 after buying an additional 584 shares during the period. Acrospire Investment Management LLC bought a new stake in AngioDynamics during the first quarter valued at approximately $149,000. Finally, Old Mutual Global Investors UK Ltd. bought a new stake in AngioDynamics during the first quarter valued at approximately $164,000. 85.84% of the stock is currently owned by hedge funds and other institutional investors.
Shares of AngioDynamics, Inc. (NASDAQ:ANGO) traded up 0.55% during midday trading on Friday, reaching $16.36. The company’s stock had a trading volume of 157,969 shares. AngioDynamics, Inc. has a 12-month low of $14.80 and a 12-month high of $18.18. The stock has a 50-day moving average of $16.22 and a 200 day moving average of $16.17. The firm has a market capitalization of $598.45 million, a P/E ratio of 119.42 and a beta of 1.15.
AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Tuesday, July 18th. The medical instruments supplier reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.16 by $0.03. The company had revenue of $86.90 million during the quarter, compared to the consensus estimate of $90.72 million. AngioDynamics had a net margin of 2.00% and a return on equity of 5.19%. The firm’s quarterly revenue was down 7.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.19 earnings per share. Equities research analysts predict that AngioDynamics, Inc. will post $0.67 EPS for the current fiscal year.
Several equities research analysts have recently commented on the company. Canaccord Genuity restated a “hold” rating and issued a $16.50 price objective on shares of AngioDynamics in a research note on Wednesday, May 31st. Cantor Fitzgerald upped their price objective on AngioDynamics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 4th. Zacks Investment Research lowered AngioDynamics from a “hold” rating to a “sell” rating in a research note on Thursday, July 20th. BidaskClub lowered AngioDynamics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Finally, Barclays PLC reduced their price objective on AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 19th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. AngioDynamics presently has an average rating of “Hold” and a consensus price target of $18.50.
In other news, CEO James C. Clemmer acquired 20,000 shares of the firm’s stock in a transaction on Thursday, July 20th. The stock was acquired at an average price of $15.64 per share, for a total transaction of $312,800.00. Following the completion of the transaction, the chief executive officer now owns 86,683 shares in the company, valued at approximately $1,355,722.12. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO James C. Clemmer acquired 5,000 shares of the firm’s stock in a transaction on Friday, July 21st. The stock was purchased at an average price of $15.79 per share, with a total value of $78,950.00. Following the transaction, the chief executive officer now owns 86,683 shares of the company’s stock, valued at approximately $1,368,724.57. The disclosure for this purchase can be found here. Insiders have purchased 25,316 shares of company stock valued at $396,806 over the last 90 days. 1.88% of the stock is currently owned by insiders.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
What are top analysts saying about AngioDynamics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AngioDynamics Inc. and related companies.